BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 21891797)

  • 1. HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
    Singh J; Khan M; Singh I
    J Lipid Res; 2011 Nov; 52(11):2056-69. PubMed ID: 21891797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes.
    Singh J; Khan M; Singh I
    Biochim Biophys Acta; 2013 Apr; 1831(4):747-58. PubMed ID: 23318275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abcd2 is a strong modifier of the metabolic impairments in peritoneal macrophages of ABCD1-deficient mice.
    Muneer Z; Wiesinger C; Voigtländer T; Werner HB; Berger J; Forss-Petter S
    PLoS One; 2014; 9(9):e108655. PubMed ID: 25255441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.
    Baarine M; Beeson C; Singh A; Singh I
    J Neurochem; 2015 May; 133(3):380-96. PubMed ID: 25393703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired very long-chain acyl-CoA β-oxidation in human X-linked adrenoleukodystrophy fibroblasts is a direct consequence of ABCD1 transporter dysfunction.
    Wiesinger C; Kunze M; Regelsberger G; Forss-Petter S; Berger J
    J Biol Chem; 2013 Jun; 288(26):19269-79. PubMed ID: 23671276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy.
    Singh J; Khan M; Singh I
    J Lipid Res; 2009 Jan; 50(1):135-47. PubMed ID: 18723473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes.
    Weber FD; Wiesinger C; Forss-Petter S; Regelsberger G; Einwich A; Weber WH; Köhler W; Stockinger H; Berger J
    Hum Mol Genet; 2014 May; 23(10):2542-50. PubMed ID: 24363066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy.
    Ofman R; Dijkstra IM; van Roermund CW; Burger N; Turkenburg M; van Cruchten A; van Engen CE; Wanders RJ; Kemp S
    EMBO Mol Med; 2010 Mar; 2(3):90-7. PubMed ID: 20166112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase.
    Singh J; Olle B; Suhail H; Felicella MM; Giri S
    J Neurochem; 2016 Jul; 138(1):86-100. PubMed ID: 26849413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy.
    Zierfuss B; Weinhofer I; Kühl JS; Köhler W; Bley A; Zauner K; Binder J; Martinović K; Seiser C; Hertzberg C; Kemp S; Egger G; Leitner G; Bauer J; Wiesinger C; Kunze M; Forss-Petter S; Berger J
    Ann Clin Transl Neurol; 2020 May; 7(5):639-652. PubMed ID: 32359032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substrate specificity overlap and interaction between adrenoleukodystrophy protein (ALDP/ABCD1) and adrenoleukodystrophy-related protein (ALDRP/ABCD2).
    Genin EC; Geillon F; Gondcaille C; Athias A; Gambert P; Trompier D; Savary S
    J Biol Chem; 2011 Mar; 286(10):8075-8084. PubMed ID: 21209459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy.
    McGuinness MC; Zhang HP; Smith KD
    Mol Genet Metab; 2001; 74(1-2):256-63. PubMed ID: 11592822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation.
    Engelen M; Schackmann MJ; Ofman R; Sanders RJ; Dijkstra IM; Houten SM; Fourcade S; Pujol A; Poll-The BT; Wanders RJ; Kemp S
    J Inherit Metab Dis; 2012 Nov; 35(6):1137-45. PubMed ID: 22447153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy.
    Weinhofer I; Forss-Petter S; Zigman M; Berger J
    Hum Mol Genet; 2002 Oct; 11(22):2701-8. PubMed ID: 12374760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astrocytes and mitochondria from adrenoleukodystrophy protein (ABCD1)-deficient mice reveal that the adrenoleukodystrophy-associated very long-chain fatty acids target several cellular energy-dependent functions.
    Kruska N; Schönfeld P; Pujol A; Reiser G
    Biochim Biophys Acta; 2015 May; 1852(5):925-36. PubMed ID: 25583114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABC subfamily D proteins and very long chain fatty acid metabolism as novel targets in adrenoleukodystrophy.
    Morita M; Shimozawa N; Kashiwayama Y; Suzuki Y; Imanaka T
    Curr Drug Targets; 2011 May; 12(5):694-706. PubMed ID: 21039332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy.
    McGuinness MC; Lu JF; Zhang HP; Dong GX; Heinzer AK; Watkins PA; Powers J; Smith KD
    Mol Cell Biol; 2003 Jan; 23(2):744-53. PubMed ID: 12509471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical aspects of X-linked adrenoleukodystrophy.
    Kemp S; Wanders R
    Brain Pathol; 2010 Jul; 20(4):831-7. PubMed ID: 20626744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy.
    Fourcade S; Ruiz M; Guilera C; Hahnen E; Brichta L; Naudi A; Portero-Otín M; Dacremont G; Cartier N; Wanders R; Kemp S; Mandel JL; Wirth B; Pamplona R; Aubourg P; Pujol A
    Hum Mol Genet; 2010 May; 19(10):2005-14. PubMed ID: 20179078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adrenoleukodystrophy: molecular pathogenesis and development of therapeutic agents].
    Morita M
    Yakugaku Zasshi; 2007 Jul; 127(7):1059-64. PubMed ID: 17603264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.